The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Amended): A compound of the formula:



wherein X is selected from the group consisting of O and S; wherein A_1 and A_2 are individually selected from the group consisting of O, S and NH;

wherein G_1 and G_3 are C_{1-4} alkyl chains;

wherein G_5 is a C_{0-4} alkyl chain; and

wherein G_2 is H or ~~selected from the group consisting of:~~



~~, and H,~~

wherein A_3 is NH and A_4 is NH_2, or

-NH-G_2 forms a urea moiety ~~are individually selected from the group consisting of O, N, and S, wherein the valencies of each O, N or S are adjusted by adding a H if needed~~;

wherein G_4 is a C_{5-8} aryl, a C_{5-8} arylsulfonylamino, an C_{5-8} arylamino; and

wherein G_6 and G_7 are individually selected from the group consisting of H, F, Cl, I, Br and a C_{1-4} alkyl.

2. (Original): The compound of claim 1, wherein X is S.

3. (Original): The compound of claim 1, wherein X is 0.

4. (Previously Amended): The compound of claim 1, wherein A_1 is NH.

5. (Original): The compound of claim 1, wherein A_1 is O.

6. (Previously Amended): The compound of claim 1, wherein A_2 is NH.

7. (Original): The compound of claim 1, wherein A_2 is O.

8. (Original): The compound of claim 1, wherein G_1 is a C_1 alkyl.

9. (Amended): The compound of claim 1, wherein $\underline{G_1}$ ~~G1~~ is $-(CH_2)_0-$.

10. (Original): The compound of claim 1, wherein G_1 is a C_2 alkyl.

11. (Original): The compound of claim 1, wherein G_1 is a C_3 alkyl.

12. (Original): The compound of claim 1, wherein G_3 is a C_1 alkyl.

13. (Original): The compound of claim 1, wherein G_3 is a C_2 alkyl.

14. (Original): The compound of claim 1, wherein G_5 is a C_1 alkyl.

15. (Original): The compound of claim 1, wherein G_5 is a C_2 alkyl.

16. (Amended): The compound of claim 1, wherein G_2 is ~~represented by the formula:~~

  ~~or H,~~

wherein A_3 is NH ~~selected from the group consisting of 0, S and N~~ and A_4 is NH_2 ~~N and wherein the valencies of each O, N or S are adjusted by adding a H if needed~~.

17. (Cancelled):

18. (Amendedl): The compound of claim 1, wherein -NH-G_2 ~~-N-G_2~~ forms a guanidino ~~containing~~ moiety.

19. (Amended): The compound of claim 1, wherein -NH-G_2 ~~-N-G_2~~ forms a urea ~~containing~~ moiety.

20. (Cancelled):

21. (Cancelled):

22. (Original): The compound of claim 1, wherein G_4 is phenylsulfonylamino.

23. (Original): The compound of claim 1, wherein G_4 is phenyl.

24. (Original): The compound of claim 1, wherein G_6 and G_7 are halogens.

25. (Original): The compound of claim 1, wherein G_6 and G_7 are the same.

26. (Original): The compound of claim 1, wherein G_6 or G_7 are F.

27. (Amended): The compound of claim 1 further represented by the formula:





wherein X is selected from the group consisting of O and S;

G_1 and G_3 are C_{1-4} alkyl chains;

G_2 is H or ~~selected from the group consisting of:~~



wherein A_3 is NH and A_4 is NH_2, or

-NH-G_2 forms a urea moiety ~~are individually selected from the group consisting of O, N, and S, wherein the valencies of each O, N or S are adjusted by adding a H if needed and G_8 is a C_{1-4} alkyl chain~~;

wherein G_4 is a C_{5-8} aryl, a C_{5-8} arylsulfonylamino, or a C_{5-8} arylamino; and

wherein G_6 and G_7 are individually selected from the group consisting of H, F, Cl, I, Br and a C_{1-4} alkyl.

28. (Previously Amended): The compound of claim 27, wherein X is S.

29. (Previously Amended): The compound of claim 27, wherein X is O.

30. (Original): The compound of claim 27, wherein G_1 is a C_1 alkyl.

31. (Original): The compound of claim 27, wherein G_1 is a C_2 alkyl.

32. (Original): The compound of claim 27, wherein G_3 is a C_1 alkyl.

33. (Original): The compound of claim 27, wherein G_3 is a C_2 alkyl.

34. (Previously Amended): The compound of claim 27, wherein G_2 is ~~represented by the formula:~~



~~or H,~~

wherein A_3 is NH ~~selected from the group consisting of 0, S and N~~ and A_4 is NH_2 ~~N and wherein the valencies of each O, N or S are adjusted by adding a H if needed~~.

35. (Cancelled):

36. (Amended): The compound of claim 27, wherein -NH-G_2 ~~-N-G_2~~ forms a guanidino ~~containing~~ moiety.

37. (Amended): The compound of claim 27, wherein -NH-G_2 ~~-N-G_2~~ forms a urea ~~containing~~ moiety.

38. (Cancelled):

39. (Cancelled):

40. (Previously Amended): The compound of claim 27, wherein G_4 is phenylsulfonylamino.

41. (Previously Amended): The compound of claim 27, wherein G_4 is phenyl.

42. (Original): A method of treating cancer comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

43. (Original): A method of treating a tumor comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

44. (Original): A method of treating a solid tumor comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

45. (Original): A method of treating metastasis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

46. (Original): A method of inhibiting angiogenesis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

47. (Original): A method of inhibiting fibronectin binding comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

48. (Original): A method of inhibiting osteopontin binding comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

49. (Original): A method of treating foot and mouth disease comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

50. (Original): A method of treating osteoporosis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

51. (Original): A method of treating restenosis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

52. (Original): A method of treating ocular diseases comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

53. (Original): A method of treating heart diseases comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

54. (Original): A method of treating arthritis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

55. (Original): A method of treating diseases in which abnormal neovascularization occurs comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

56. (Amended): A method of inhibiting $\underline{\alpha_v}$ ~~αv~~ integrins comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

57. (Original): A method of inhibiting $\alpha_v\beta_3$ integrin comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

58. (Original): A pharmaceutical composition for treating cancer comprising a pharmaceutically effective amount of a compound of claim 1.

59. (Original): A pharmaceutical composition for treating tumor comprising a pharmaceutically effective amount of a compound of claim 1.

60. (Original): A pharmaceutical composition for treating solid tumor comprising a pharmaceutically effective amount of a compound of claim 1.

61. (Original): A pharmaceutical composition for treating metastasis comprising a pharmaceutically effective amount of a compound of claim 1.

62. (Original): A pharmaceutical composition for inhibiting angiogenesis comprising a pharmaceutically effective amount of a compound of claim 1.

63. (Original): A pharmaceutical composition for inhibiting fibronectin binding comprising a pharmaceutically effective amount of a compound of claim 1.

64. (Original): A pharmaceutical composition for inhibiting osteopontin binding comprising a pharmaceutically effective amount of a compound of claim 1.

65. (Original): A pharmaceutical composition for treating foot and mouth disease comprising a pharmaceutically effective amount of a compound of claim 1.

66. (Original): A pharmaceutical composition for treating osteoporosis comprising a pharmaceutically effective amount of a compound of claim 1.

67. (Original): A pharmaceutical composition for treating restenosis comprising a pharmaceutically effective amount of a compound of claim 1.

68. (Original): A pharmaceutical composition for treating ocular diseases comprising a pharmaceutically effective amount of a compound of claim 1.

69. (Original): A pharmaceutical composition for treating heart diseases comprising a pharmaceutically effective amount of a compound of claim 1.

70. (Original): A pharmaceutical composition for treating arthritis comprising a pharmaceutically effective amount of a compound of claim 1.

71. (Original): A pharmaceutical composition for treating diseases in which abnormal neovascularization occurs comprising a pharmaceutically effective amount of a compound of claim 1.

72. (Original): A pharmaceutical composition for inhibiting α_v integrins comprising a pharmaceutically effective amount of a compound of claim 1.

73. (Original): A pharmaceutical composition for inhibiting $\alpha_v\beta_3$ integrin comprising a pharmaceutically effective amount of a compound of claim 1.

74. (Previously Amended): A combination useful for the treatment of cancer comprising at least one compound of claim 1 and at least one other anticancer agent or antiangiogenic agent.

75. (Previously Amended): A combination useful for the treatment of cancer comprising at least one compound of claim 1 and at least one other anticancer agent selected from the group consisting of alkylating agents, antitumor antibiotics, antimetabolites, biological agents, hormonal agents, nitrogen mustard derivatives and plant alkaloids.